Improving the detection of carbapenemase-producing organisms (CPO) in a low-prevalence setting: evaluation of four commercial methods and implementation of an algorithm of testing
- PMID: 29388538
- DOI: 10.1099/jmm.0.000674
Improving the detection of carbapenemase-producing organisms (CPO) in a low-prevalence setting: evaluation of four commercial methods and implementation of an algorithm of testing
Abstract
Purpose: Carbapenemase-producing organisms (CPOs) can be resistant to almost all β-lactams and represent an increasing threat in healthcare facilities. Detection of these organisms in routine diagnostic laboratories is difficult; here we evaluate four commercially available CPO detection assays and assess their suitability for the clinical laboratory.
Methodology: A panel of 95 clinical multidrug-resistant organisms (22 NDM, 24 OXA-48, 19 VIM, 4 OXA-23, 3 KPC, 4 NDM+OXA-48, 1 OXA23+NDM, 1 IMI, 1 IMP-1, 9 ESBL, 3 derepressed AmpC and 4 inducible AmpC producers) were tested by the RESIST-3 O.K.N., RapidEC CarbaNP, Acuitas Resistome and Xpert Carba-R assays.Results/Key Findings. The commercial assays performed well, with high sensitivities (96.2-100 %) and specificities (all, 100 %). The RapidEC CarbaNP and Acuitas Resistome were able to detect the broadest range of carbapenemase genotypes. The RESIST-3 O.K.N. and Xpert CarbaR had the shortest turnaround times, whilst the RapidEC CarbaNP was the only assay included in this study that could detect previously undescribed genotypes.
Conclusion: Using an algorithm of the RapidEC CarbaNP, followed by either the RESIST-3 O.K.N. (Enterobacteriaceae) or the Xpert Carba-R (Pseudomonas aeruginosa and Acinetobacter spp.) on suspect CPOs allowed rapid in-house detection and genotyping of a high proportion of CPOs, reducing turnaround time by up to 7 days.
Keywords: Carbapenemase; algorithm; detection.
Similar articles
-
Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae.J Antimicrob Chemother. 2015 Nov;70(11):3014-22. doi: 10.1093/jac/dkv213. Epub 2015 Aug 9. J Antimicrob Chemother. 2015. PMID: 26260131
-
High-Stringency Evaluation of the Automated BD Phoenix CPO Detect and Rapidec Carba NP Tests for Detection and Classification of Carbapenemases.J Clin Microbiol. 2017 Dec;55(12):3437-3443. doi: 10.1128/JCM.01215-17. Epub 2017 Oct 4. J Clin Microbiol. 2017. PMID: 28978681 Free PMC article.
-
Evaluation of three molecular carbapenemase tests: Eazyplex SuperBug complete B, Novodiag CarbaR+, and Amplidiag CarbaR+MCR.J Microbiol Methods. 2021 Jan;180:106105. doi: 10.1016/j.mimet.2020.106105. Epub 2020 Nov 18. J Microbiol Methods. 2021. PMID: 33217483
-
Identification and screening of carbapenemase-producing Enterobacteriaceae.Clin Microbiol Infect. 2012 May;18(5):432-8. doi: 10.1111/j.1469-0691.2012.03815.x. Clin Microbiol Infect. 2012. PMID: 22507110 Review.
-
Carba NP test for the detection of carbapenemase-producing Pseudomonas aeruginosa.Med Mal Infect. 2020 Sep;50(6):466-479. doi: 10.1016/j.medmal.2019.12.002. Epub 2019 Dec 30. Med Mal Infect. 2020. PMID: 31899068 Review.
Cited by
-
Resistome-based surveillance identifies ESKAPE pathogens as the predominant gram-negative organisms circulating in veterinary hospitals.Front Microbiol. 2023 Sep 7;14:1252216. doi: 10.3389/fmicb.2023.1252216. eCollection 2023. Front Microbiol. 2023. PMID: 37744932 Free PMC article.
-
Evaluation of Xpert Carba-R Assay for the Detection of Carbapenemase Genes in Gram-Negative Bacteria.Biomed Res Int. 2021 Apr 8;2021:6614812. doi: 10.1155/2021/6614812. eCollection 2021. Biomed Res Int. 2021. PMID: 33928150 Free PMC article.
-
Epidemiology and control measures of an OXA-48-producing Enterobacteriaceae hospital outbreak.Infect Prev Pract. 2020 May 21;2(3):100021. doi: 10.1016/j.infpip.2019.100021. eCollection 2020 Sep. Infect Prev Pract. 2020. PMID: 34368707 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous